Does the media favor IRWD or ABBV?

In the previous week, AbbVie had 44 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 51 mentions for AbbVie and 7 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 0.92 beat Ironwood Pharmaceuticals' score of 0.75 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 31 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Positive

Does the media refer more to NVAX or IRWD?

In the previous week, Novavax had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 8 mentions for Novavax and 7 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.75 beat Novavax's score of 0.24 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INVA or IRWD?

In the previous week, Innoviva had 2 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for Innoviva and 7 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.75 beat Innoviva's score of 0.09 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRWD or MNKD?

In the previous week, MannKind had 8 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 15 mentions for MannKind and 7 mentions for Ironwood Pharmaceuticals. MannKind's average media sentiment score of 0.81 beat Ironwood Pharmaceuticals' score of 0.75 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Ironwood Pharmaceuticals (IRWD) Competitors

$3.40 +0.16 (+4.78%)

Closing price 03:59 PM Eastern

Extended Trading

$3.44 +0.05 (+1.35%)

As of 05:44 PM Eastern

Compare

IRWD vs. ABBV, BCRX, NVAX, INVA, and MNKD

Should you buy Ironwood Pharmaceuticals stock or one of its competitors? MarketBeat compares Ironwood Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ironwood Pharmaceuticals include AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), and MannKind (MNKD). These companies are all part of the "medical" sector.

How does Ironwood Pharmaceuticals compare to AbbVie?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$361.51M	1.53	$24.02M	$0.60	5.66
AbbVie	$61.16B	6.49	$4.23B	$2.03	110.74

Ironwood Pharmaceuticals has a net margin of 28.26% compared to AbbVie's net margin of 5.79%. Ironwood Pharmaceuticals' return on equity of -39.65% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
AbbVie	5.79%	-576.45%	13.39%

70.2% of AbbVie shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ironwood Pharmaceuticals presently has a consensus target price of $6.23, suggesting a potential upside of 83.60%. AbbVie has a consensus target price of $253.43, suggesting a potential upside of 12.73%. Given Ironwood Pharmaceuticals' higher probable upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

In the previous week, AbbVie had 44 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 51 mentions for AbbVie and 7 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 0.92 beat Ironwood Pharmaceuticals' score of 0.75 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	31 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Summary

AbbVie beats Ironwood Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

BioCryst Pharmaceuticals has higher revenue and earnings than Ironwood Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72M	2.44	$263.86M	-$1.78	N/A
Ironwood Pharmaceuticals	$361.51M	1.53	$24.02M	$0.60	5.66

Ironwood Pharmaceuticals has a net margin of 28.26% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Ironwood Pharmaceuticals' return on equity of -39.65% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

BioCryst Pharmaceuticals presently has a consensus price target of $20.70, suggesting a potential upside of 143.73%. Ironwood Pharmaceuticals has a consensus price target of $6.23, suggesting a potential upside of 83.60%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe BioCryst Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

In the previous week, Ironwood Pharmaceuticals had 7 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 7 mentions for Ironwood Pharmaceuticals and 0 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.82 beat Ironwood Pharmaceuticals' score of 0.75 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
BioCryst Pharmaceuticals	Very Positive
Ironwood Pharmaceuticals	Positive

Summary

BioCryst Pharmaceuticals beats Ironwood Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Novavax has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Novavax has higher revenue and earnings than Ironwood Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.49	$440.30M	-$0.58	N/A
Ironwood Pharmaceuticals	$361.51M	1.53	$24.02M	$0.60	5.66

In the previous week, Novavax had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 8 mentions for Novavax and 7 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.75 beat Novavax's score of 0.24 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax presently has a consensus target price of $12.13, suggesting a potential upside of 18.99%. Ironwood Pharmaceuticals has a consensus target price of $6.23, suggesting a potential upside of 83.60%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Ironwood Pharmaceuticals beats Novavax on 10 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Innoviva?

Innoviva (NASDAQ:INVA) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Innoviva has a net margin of 119.89% compared to Ironwood Pharmaceuticals' net margin of 28.26%. Innoviva's return on equity of 33.33% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Innoviva currently has a consensus price target of $36.20, suggesting a potential upside of 63.36%. Ironwood Pharmaceuticals has a consensus price target of $6.23, suggesting a potential upside of 83.60%. Given Ironwood Pharmaceuticals' higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, Innoviva had 2 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for Innoviva and 7 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.75 beat Innoviva's score of 0.09 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has higher revenue and earnings than Ironwood Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.98	$271.17M	$6.01	3.69
Ironwood Pharmaceuticals	$361.51M	1.53	$24.02M	$0.60	5.66

99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Innoviva has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Summary

Innoviva beats Ironwood Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to MannKind?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

In the previous week, MannKind had 8 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 15 mentions for MannKind and 7 mentions for Ironwood Pharmaceuticals. MannKind's average media sentiment score of 0.81 beat Ironwood Pharmaceuticals' score of 0.75 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$361.51M	1.53	$24.02M	$0.60	5.66
MannKind	$360.78M	3.01	$5.86M	-$0.07	N/A

49.5% of MannKind shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, indicating a potential upside of 83.60%. MannKind has a consensus target price of $8.97, indicating a potential upside of 154.79%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ironwood Pharmaceuticals has a net margin of 28.26% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
MannKind	-6.63%	-11.21%	-3.92%

Ironwood Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, MannKind has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Summary

MannKind beats Ironwood Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRWD vs. The Competition

Export

Metric	Ironwood Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$553.58M	$2.97B	$6.44B	$12.46B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	5.66	18.12	23.87	24.36
Price / Sales	1.53	303.59	521.52	117.07
Price / Cash	12.74	55.72	41.27	57.13
Price / Book	-2.11	3.95	9.99	6.73
Net Income	$24.02M	$75.85M	$3.56B	$337.03M
7 Day Performance	-5.69%	-1.13%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	463.86%	23.03%	28.77%	33.98%

Ironwood Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRWD Ironwood Pharmaceuticals	2.5248 of 5 stars	$3.40 +4.8%	$6.23 +83.6%	+431.2%	$553.58M	$361.51M	5.66	220	Analyst Revision
ABBV AbbVie	4.7619 of 5 stars	$212.63 -2.3%	$253.43 +19.2%	+16.1%	$384.67B	$62.82B	104.74	57,000	Trending News Gap Up
BCRX BioCryst Pharmaceuticals	3.4167 of 5 stars	$8.57 -3.8%	$20.70 +141.5%	-26.3%	$2.26B	$874.84M	N/A	530	Positive News Analyst Forecast
NVAX Novavax	2.0344 of 5 stars	$10.51 -4.2%	$12.13 +15.4%	+40.5%	$1.80B	$1.12B	N/A	1,990
INVA Innoviva	3.3468 of 5 stars	$21.51 +0.4%	$36.20 +68.3%	+5.3%	$1.59B	$420.69M	3.58	100	Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRWD) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BCRX, NVAX, INVA, and MNKD

How does Ironwood Pharmaceuticals compare to AbbVie?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Summary

How does Ironwood Pharmaceuticals compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BCRX, NVAX, INVA, and MNKD

How does Ironwood Pharmaceuticals compare to AbbVie?

Which has better earnings & valuation, IRWD or ABBV?

Is IRWD or ABBV more profitable?

Do institutionals and insiders believe in IRWD or ABBV?

Do analysts rate IRWD or ABBV?

Does the media favor IRWD or ABBV?

Which has more risk & volatility, IRWD or ABBV?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Which has preferable earnings and valuation, BCRX or IRWD?

Is BCRX or IRWD more profitable?

Do analysts prefer BCRX or IRWD?

Do insiders and institutionals hold more shares of BCRX or IRWD?

Which has more risk and volatility, BCRX or IRWD?

Does the media favor BCRX or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Which has more volatility & risk, NVAX or IRWD?

Is NVAX or IRWD more profitable?

Which has better valuation & earnings, NVAX or IRWD?

Does the media refer more to NVAX or IRWD?

Do analysts recommend NVAX or IRWD?

Do insiders & institutionals believe in NVAX or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Is INVA or IRWD more profitable?

Do analysts recommend INVA or IRWD?

Does the media refer more to INVA or IRWD?

Which has preferable earnings and valuation, INVA or IRWD?

Do institutionals and insiders believe in INVA or IRWD?

Which has more risk and volatility, INVA or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to MannKind?

Does the media prefer IRWD or MNKD?

Which has better earnings and valuation, IRWD or MNKD?

Do institutionals & insiders believe in IRWD or MNKD?

Do analysts rate IRWD or MNKD?

Is IRWD or MNKD more profitable?

Which has more risk and volatility, IRWD or MNKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools